---
reference_id: "PMID:38044190"
title: Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease.
authors:
- Gallo-Fernández I
- López-Aguilera J
- González-Manzanares R
- Pericet-Rodriguez C
- Carmona-Rico MJ
- Perea-Armijo J
- Castillo-Domínguez JC
- Anguita-Sánchez M
- en representación del Grupo de Trabajo de Insuficiencia Cardiaca del Hospital Reina Sofía
journal: Med Clin (Barc)
year: '2024'
doi: 10.1016/j.medcli.2023.10.006
content_type: abstract_only
---

# Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease.
**Authors:** Gallo-Fernández I, López-Aguilera J, González-Manzanares R, Pericet-Rodriguez C, Carmona-Rico MJ, Perea-Armijo J, Castillo-Domínguez JC, Anguita-Sánchez M, en representación del Grupo de Trabajo de Insuficiencia Cardiaca del Hospital Reina Sofía
**Journal:** Med Clin (Barc) (2024)
**DOI:** [10.1016/j.medcli.2023.10.006](https://doi.org/10.1016/j.medcli.2023.10.006)

## Content

1. Med Clin (Barc). 2024 Mar 8;162(5):205-212. doi: 10.1016/j.medcli.2023.10.006.
 Epub 2023 Dec 2.

Clinical differences between transthyretin cardiac amyloidosis and hypertensive 
heart disease.

[Article in English, Spanish]

Gallo-Fernández I(1), López-Aguilera J(2), González-Manzanares R(1), 
Pericet-Rodriguez C(1), Carmona-Rico MJ(3), Perea-Armijo J(4), 
Castillo-Domínguez JC(1), Anguita-Sánchez M(1); en representación del Grupo de 
Trabajo de Insuficiencia Cardiaca del Hospital Reina Sofía.

Author information:
(1)Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital 
Universitario Reina Sofía, Córdoba, España; Instituto de Investigación Biomédica 
de Córdoba, IMIBIC, Córdoba, España.
(2)Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital 
Universitario Reina Sofía, Córdoba, España; Instituto de Investigación Biomédica 
de Córdoba, IMIBIC, Córdoba, España. Electronic address: mircardjla@gmail.com.
(3)Universidad de Córdoba, Córdoba, España.
(4)Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital 
Universitario Reina Sofía, Córdoba, España; Instituto de Investigación Biomédica 
de Córdoba, IMIBIC, Córdoba, España; Universidad de Córdoba, Córdoba, España.

Comment on
    Lancet Glob Health. 2020 Aug;8(8):e1003-e1017. doi: 
10.1016/S2214-109X(20)30264-3.

INTRODUCTION: A significant percentage of patients eventually diagnosed with 
cardiac transthyretin amyloidosis (TTRA) was previously diagnosed with 
hypertensive heart disease (HHD), since both conditions usually present with 
heart failure (HF) with preserved ejection fraction (HFpEF) and ventricular 
hypertrophy. Our objectives were to evaluate the clinical, electrocardiographic 
and echocardiographic differences, and to analyse whether there exists a 
differential prognosis between these two nosological entities.
MATERIALS AND METHODS: We retrospectively included all patients with HHD for 
whom a cardiac scintigraphy with 99mTc-diphosphonate (GDPD) and a free light 
chains test in blood and urine were ordered for ATTR screening in our centre, in 
the period between 2016 and 2021. Those diagnosed with other types of 
amyloidosis were excluded from the analysis.
RESULTS: A total of 72 patients were analyzed: 33 were finally diagnosed with 
TTRA and 39 with CHTA. Patients with TTRA had higher levels of ultrasensitive 
troponin I (TnI-US) and N-terminal brain natriuretic propeptide (NT-ProBNP); in 
electrocardiography (ECG) they presented a pseudo-infarction pattern more 
frequently as well as conduction disturbances; in echocardiography (TTE) they 
presented a higher degree of ventricular hypertrophy, left ventricular 
dysfunction and worse diastolic function parameters, with elevated filling 
pressures. In the 4-year follow-up, the ATTR group showed greater need for 
pacemaker (PCM), with no evidence regarding mortality, development of atrial 
fibrillation (AF), or more admissions for heart failure (HF).
CONCLUSIONS: In our series, patients with TTRA showed clinical, 
electrocardiographic and echocardiographic differences compared to patients with 
HHD, with increased risk of need for PCM.

Copyright © 2023. Published by Elsevier España, S.L.U.

DOI: 10.1016/j.medcli.2023.10.006
PMID: 38044190 [Indexed for MEDLINE]